ETC
TVRD

Exchange Traded Concepts’s Tvardi Therapeutics TVRD Stock Holding History

Exchange Traded Concepts’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,347
Closed -$692K – 1266
2021
Q2 		$692K Buy
+1,347
New +$854K 0.02% 401

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Exchange Traded Concepts's TVRD Position: Q3 2021 in Review

Exchange Traded Concepts sold out of Tvardi Therapeutics (TVRD) in Q3 2021, closing a stake of 1,347 shares — an estimated $692K sold.

Exchange Traded Concepts first reported a position in TVRD in Q2 2021 and held it in 1 quarter. The position peaked at $692K in Q2 2021. 169 funds tracked by Wall St. Rank hold TVRD as of Q3 2021.

  • Exchange Traded Concepts reported no remaining Tvardi Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Exchange Traded Concepts sold 1,347 Tvardi Therapeutics shares in Q3 2021, an estimated $692K.
  • Exchange Traded Concepts first reported a position in Tvardi Therapeutics in Q2 2021 and held it in 1 quarter.
  • Exchange Traded Concepts's Tvardi Therapeutics position peaked at $692K in Q2 2021.
  • 169 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2021.

Based on Exchange Traded Concepts's 13F filing for Q3 2021, filed 18 Oct 2021.